Standard BioTools Inc. Effective Income Tax Rate Reconciliation, Tax Contingency, Amount
Standard BioTools Inc. (LAB) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Amount of $841.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingencies · last filed 2026-03-16
- Standard BioTools Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2025 was $841.00K.
- Standard BioTools Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2024 was -$1.42M, a 7210.00% decline from fiscal 2023.
- Standard BioTools Inc. effective income tax rate reconciliation, tax contingency, amount for fiscal 2023 was $20.00K.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 12 month |
|---|---|
| 2025-12-31 | $841.00K 10-K · filed 2026-03-16 |
| 2024-12-31 | -$1.42M 10-K · filed 2026-03-16 |
| 2023-12-31 | $20.00K 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |